Diseases, Conditions, Syndromes

Denosumab promising for TDT-induced osteoporosis treatment

(HealthDay)—Denosumab (DNM), a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL), may be beneficial for managing transfusion-dependent thalassemia (TDT)-induced osteoporosis, ...

Oncology & Cancer

Modifying the major model of a modern major mouse model

If a new anti-cancer drug shows promise in a Petri dish, often the next step is to test the drug's effect in mice. This system tends to work well with drugs that directly target cancer, but breaks down with immunotherapies. ...

page 10 from 18